An evaluation of the management of patients with cerebral metastases from malignant melanoma.
D000328:Adult; D000368:Aged; D000577:Amides / Q000627:therapeutic use; D001921:Brain / Q000528:radiation effects; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D003128:Coma / Q000517:prevention & control; D003907:Dexamethasone / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006261:Headache / Q000517:prevention & control; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000473:pathology*; D008875:Middle Aged; D009325:Nausea / Q000517:prevention & control; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000532:radiotherapy*; D009461:Neurologic Manifestations; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D014226:Triazenes / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use; D014839:Vomiting / Q000517:prevention & control
D000577:Amides; D007093:Imidazoles; D009607:Nitrosourea Compounds; D014226:Triazenes; D014750:Vincristine; D003907:Dexamethasone; D011241:Prednisone